Acute Ischemic Stroke Diagnosis and Treatment Market

Ischemic stroke is caused by a dysfunction in the supply of blood to the brain due to emboli, thrombus or atherosclerosis occurring in cerebral arteries. According to a World Health Organization (WHO) estimate, around 17 million people die every year due to cardiovascular diseases. Heart attacks and strokes respectively account for the highest number of deaths due to cardiovascular diseases, globally. The statistics of the Centres for Disease Control and Prevention suggest that about 87% of all strokes are ischemic strokes. Stroke is one of the leading cause of long term disability, occurring at a higher rate in the old age population. Moreover, stroke leads to 1 out of every 20 deaths, costing around $34 billion to U.S. annually. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.

The two major factors propelling the growth of the acute ischemic stroke diagnosis and treatment market are; large patient pools and a concerning rise in population at a higher risk of developing stroke in the near future. Rising incidence of diabetes along with heavy tobacco users and an increase in the ageing population are significant factors that determine the market growth. However, the high cost of treatment, lack of transparent reimbursement policies, and limited availability of expertise; are likely to restrict the market growth.

The global ischemic stroke diagnosis and treatment market is segmented on the basis of type and geography. According to type, the market is segmented into, diagnostics and therapeutics. The diagnostic market is further segmented into Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and Blood tests. The therapeutic market further segments into Tissue Plasminogen Activator Anticoagulant, Antiplatelet and Antihypertensive. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.

New Product launches and collaborations are some of the key strategies adopted by leading industry players. In March, 2015, FDA approved WATCHMAN, a left atrial appendage closure device designed to prevent stroke in patients with atrial fibrillation. Silk Road Medical, Inc. has launched an Anti-Stroke Enroute Device, a transcarotid neuroprotection system, designed to access the common carotid artery through a minimally invasive technique. NeuroVive Pharmaceutical AB, entered into collaboration with BBB Therapeutics, for development of the NVP014 drug candidate used in the treatment of ischemic strokes.

The companies profiled in this report include, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc.

KEY MARKET BENEFITS:

• Comprehensive analysis of factors that drive and restrict the growth of the global acute ischemic stroke diagnosis and treatment market is provided
• The report provides a comprehensive analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
• An in-depth analysis of the key segments of the market demonstrate the types of therapeutics along with the diagnostics that currently used in the acute ischemic stroke market
• SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
• The acute ischemic stroke diagnosis and treatment market scenario is comprehensively analysed in accordance to the key regions
• Competitive intelligence highlights the business practises followed by leading market players across geographies

 Acute Ischemic Stroke Diagnosis and Treatment Market Report Highlights